Nebraska Finalizes Medical Cannabis Rules With Strict Limits

Nebraska’s voter-approved medical cannabis program finally has permanent rules on the books, and they rank among the most restrictive in the country. The finalized regulations bar patients from smoking, vaping, or eating their medicine, cap the entire state at 12 dispensaries, and prohibit any product stronger than 60% THC.

Governor Jim Pillen approved the permanent regulations on July 1, 2026, a day after Attorney General Mike Hilgers signed off on their legality. The two approvals were the final gates for rules the Nebraska Medical Cannabis Commission adopted in April 2026, and they close out a milestone left pending when the commission cleared the state’s first legal cultivator weeks earlier. Under state law, the rules take effect five days after they are filed with the secretary of state, replacing a temporary set that had been due to expire in mid-July.

What the rules allow

The regulations sharply narrow what “medical cannabis” means in Nebraska. Smokable and vaping products are banned outright, as are edibles of any kind. Patients are limited to oral tablets, capsules, tinctures, topical preparations, suppositories, transdermal patches, and liquids for nebulizers or inhalers.

The program’s hard limits run through the entire supply chain:

• No smokable, vaping, or edible products; potency capped at 60% THC or 40 milligrams of THC per dose.
• Patients limited to five ounces over any 30-day period, with a tighter sub-limit on the delta-9 THC obtainable from a single dispensary.
• Just 12 dispensaries statewide, assigned by judicial district — a distribution that under current population patterns concentrates access in a handful of the most populous counties.
• Only four cultivators, all four already licensed, each capped at 1,250 flowering plants, plus up to four product manufacturers and 12 transporters.

The effect is a tightly rationed market. Even with the first grower now legally in the ground, the rules cap how much medicine can be produced and how few points of sale patients will ever reach.

An attorney general who signed with reservations

Hilgers’s approval was narrow and pointed. He framed his review as a legal check rather than an endorsement, concluding only that the rules do not clearly violate the state or federal constitutions on their face. Then he warned that the commission’s future rules might not clear the same bar: any regulations that allow access “untethered to a plausibly medical purpose without adequate patient protections are ‘medical’ in name only and may slip into a preempted recreational marijuana scheme.”

The attorney general also used the letter to stress that the program’s entire legal foundation remains contested. His office is backing a lawsuit, Kuehn v. Evnen, now before the Nebraska Supreme Court, that alleges fraud in the signature drive that put the 2024 measures on the ballot. If the court agrees the underlying act never qualified, Hilgers noted, the regulations built on it would lose their statutory footing.

That posture drew sharp criticism. Nebraska voters had approved the two measures decisively in November 2024 — roughly 71% backing legalization and 67% backing the regulatory commission. Nebraskans for Medical Marijuana, which sponsored the initiatives, dismissed the signing as an election-year gesture from an official who has fought the program in court. Jocelyn Brasher, the Democratic nominee challenging Hilgers this year, accused him of claiming credit for the rules while continuing to litigate against the law that authorizes them. The fight tracks a wider pattern in conservative states, where officials have moved to blunt voter-driven cannabis measures.

What patients and operators next

Finalized rules do not translate into available medicine. No Nebraska physician has publicly agreed to recommend cannabis since the law took effect in December 2024, and the Legislature declined to pass protections for providers who do — leaving the state’s recommendation directory effectively empty. Advocates warn that dispensaries could eventually open with no legal path for patients to qualify to shop in them.

Operators face a constraint of their own. The rules also carry in-state ownership and residency requirements that effectively shut out the large multistate operators that dominate medical markets in neighboring states. First retail sales are not expected before late 2026 and could slip into 2027.

The program also sits in an unsettled federal posture. A Trump administration order in spring 2026 moved state-licensed medical cannabis to Schedule III, a reclassification Nebraska — under Hilgers — is helping to challenge, even as other states resist the change. Hilgers’s own letter leaned on a long-standing congressional budget rider that bars the Justice Department from spending money to interfere with state medical cannabis programs, while noting that the current version of that rider does not yet list Nebraska. The commission meets next on July 20, 2026.